Priority Review for Keytruda in broad NSCLC indication

Merck & Co. Inc. (NYSE:MRK) said FDA accepted and granted Priority Review to an sBLA for Keytruda pembrolizumab in a broader first-line non-small cell

Read the full 240 word article

User Sign In